Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00191399 · ClinicalTrials.gov registry record · Phase 4
Bipolar Depression Study: Bipolar Depression Assessment Study on Treatment Response
A Phase 4 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 4
- Development phase
- 150
- Enrollment target
NCT00191399 is a Phase 4 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 150 participants.
The verdict
NCT00191399, a Phase 4 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 150 participants
- Enrollment target
Study Summary
The primary objective of this study is to assess the efficacy of olanzapine and fluoxetine combined on all the visits as compared with the baseline visit in patients with bipolar disorder, measured by the total score of the Montgomery-Asberg Depression Rating Scale (MADRS).
Interventions
- DRUG Olanzapine
- DRUG Fluoxetine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2004-05 |
| Est. Completion | 2006-03 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00191399
The ClinicalTrials.gov registry entry for NCT00191399 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Olanzapine is the first listed.
NCT00191399 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00191399 about?
NCT00191399 is a clinical study titled "Bipolar Depression Study: Bipolar Depression Assessment Study on Treatment Response". The primary objective of this study is to assess the efficacy of olanzapine and fluoxetine combined on all the visits as compared with the baseline visit in patients with bipolar disorder, measured by the total score of the Montgomery-Asberg Depression Rating Scale (MADRS).
What is the current status of trial NCT00191399?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 150 participants. The study started on 2004-05. Estimated completion is 2006-03.
What interventions are being tested in trial NCT00191399?
The interventions under investigation include: Olanzapine (DRUG), Fluoxetine (DRUG).
Who is sponsoring clinical trial NCT00191399?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.